STAXYN
LOE ApproachingNDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jun 2010
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STAXYN (vardenafil) is an orally disintegrating tablet formulation of a phosphodiesterase type 5 (PDE5) inhibitor approved for erectile dysfunction. It works by inhibiting PDE5 in the corpus cavernosum, increasing cGMP levels and promoting smooth muscle relaxation to enable penile blood flow during sexual stimulation. The drug requires sexual stimulation to be effective and has high selectivity for PDE5 over other phosphodiesterases (>15-fold relative to PDE6).
LOE Approaching2.4 years to LOE
Product approaching loss of exclusivity in 2.5 years; brand team likely in transition or defensive positioning mode with reduced hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on STAXYN at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.